T-Vec

Oncorus CEO Ted Ashburn
Biotech

Oncorus raises $80M for 2-front oncolytic virus R&D push

The series B round equips Oncorus to move its lead asset into the clinic and nominate an intravenously administered viral candidate early next year.
Nick Paul Taylor Aug 21, 2019 7:00am
melanoma

A 3-pronged attack on melanoma

Dec 12, 2018 2:00pm
An aerial photograph of Oxford

Oncolytics player Replimune bags $55M to hit clinical POC

Sep 8, 2017 9:50am
Roger Perlmutter

Merck talks I/O combo strategy as Keytruda nabs first-line NSCLC

Oct 25, 2016 2:47pm